17-316 - Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Status: openINCB 01158-101 (CX-1158-101) - Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Treatment for Lung Cancer
Contact Us
If you have questions about this trial or are interested in participating, please contact Wendy Blount, director of clinical trials, at (251) 445-9834 or wlblount@health.southalabama.edu.
Description
This study is an open-label Phase 1 evaluation of CB-1158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors. IRB Number 17-316
Sponsors
This trial is sponsored by Incyte Corporation.Providers Associated With This Trial
Principle Investigator
Sub Investigators
![Thomas Butler]()
View ProfileThomas W. Butler, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Oncology![Daniel Cameron]()
View ProfileDaniel G. Cameron, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Clinical Oncology
This link will open in a new tab or window.